ALPS Trial design: Patients with adult nontraumatic out-of-hospital cardiac arrest (OOHCA) and persistent or recurrent VT/VF after ≥1 shock were randomized.

Slides:

Advertisements

Similar presentations

CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.

Advertisements

Amiodarone Use in Cardiac Surgical Resuscitation

Prevention of Recurrent Venous Thromboembolism N Engl J Med Apr ;348(15) : PREVENT (Warfarin) Trial.

CAST: Cardiac Arrhythmia Suppression Trial Purpose To determine whether therapy with class Ic antiarrhythmics to suppress asymptomatic or mildly symptomatic.

BEST: Beta-blocker Evaluation Survival Trial Purpose To determine whether the β-blocker bucindolol reduces morbidity and mortality in patients with advanced.

Greg Gaines PA-S A RANDOMIZED TRIAL OF GLUTAMINE AND ANTIOXIDANTS IN CRITICALLY ILL PATIENTS.

Introduction Therapeutic hypothermia has been shown to improve survival and neurologic outcome in patients resuscitated after ventricular fibrillation.

Induced Hypothermia After VF Cardiac Arrest Improves Outcomes Summary and Comment by Kristi L. Koenig, MD, FACEP Published in Journal Watch Emergency Medicine.

Do IV Meds Matter in Out-of-Hospital Cardiac Arrest? Summary and Comment by John A. Marx, MD, FAAEM Published in Journal Watch Emergency Medicine December.

Dallas 2015 TFQO: Jonathan Witt (COI #418) EVREVs: Steve Lin (COI #137), Thomas Pellis (COI #186) and Katie Dainty (COI #) Taskforce: ALS ALS 428 : Antiarrhythmic.

COPERNICUS: Carvedilol Prospective Randomized Cumulative Survival trial Purpose To assess the effect of carvedilol, a β 1 -, β 2 - and α 1 -receptor blocker,

The AURORA Trial Source: Holdaas H, Holme I, Schmieder RE, et al. Rosuvastatin in diabetic hemodialysis patient. J Am Soc Nephrol. 2011;22(7):1335–1341.

(p for noninferiority = 0.01)

IRIS Trial design: Patients without diabetes with a history of stroke or TIA within 6 months, with objective evidence of insulin resistance (HOMA-IR value.

CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.

SOCRATES Trial design: Patients with acute ischemic stroke were randomized in a 1:1 fashion to receive either ticagrelor 180 mg load + 90 mg BID or aspirin.

EARLY-BAMI Trial design: Patients presenting with STEMI with a plan for primary PCI, and without evidence of cardiogenic shock, were randomized to either.

Recently Diagnosed vs Chronic HF Associated with Better Outcomes

(p < for group 1 or 2 vs. group 3)

IMPI Trial design: Participants with TB pericarditis and risk for HIV were randomized to prednisolone (n = 706) vs. placebo (n = 694) and to M. indicus.

SAVE Trial design: Patients with moderate to severe obstructive sleep apnea (OSA) and known CV disease were randomized in a 1:1 fashion to either CPAP.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

BENEFIT Trial design: Patients with positive serologic tests for T. Cruzi and cardiomyopathy were randomized to benznidazole 300 mg daily for days.

DANISH Trial design: Patients with nonischemic cardiomyopathy were randomized to ICD implantation (n = 556) versus usual care (n = 560). Results (p = 0.28)

EUCLID Trial design: Patients with peripheral arterial disease (PAD) were randomized to ticagrelor 90 mg twice daily (n = 6,930) vs. clopidogrel 75 mg.

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

ATLANTIC Trial design: Participants with STEMI being transported for primary PCI were randomized in the ambulance to ticagrelor 180 mg (n = 909) vs. placebo.

AARDVARK Trial design: Patients with small abdominal aortic aneuryms (AAAs) were randomized in a 1:1:1 fashion to either perindopril 10 mg once daily,

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

(p for noninferiority = )

Angiography-guided PCI

EMPA-REG OUTCOME Trial design: Patients with type 2 diabetes mellitus (DM2) at high risk for CV events were randomized to receive in a 1:1:1 fashion either.

Primary endpoint at 1 year

EXCEL Trial design: Patients with unprotected left main disease were randomized to either PCI with an Xience everolimus-eluting stent (EES) or CABG. They.

MAGIC-AF Trial design: Patients with persistent atrial fibrillation (AF) and remaining in AF after pulmonary vein isolation alone were randomized to either.

Compare-Acute Trial design: STEMI patients undergoing primary PCI were randomized to fractional flow reserve (FFR)-guided complete revascularization (n.

PARADIGM-HF Trial design: Participants with NYHA class II-IV and LVEF ≤40% were randomized to LCZ mg twice daily (n = 4,187) vs. enalapril 10 mg.

VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =

SIGNIFY Trial design: Participants with stable coronary artery disease without clinical heart failure and resting heart rate >70 bpm were randomized to.

Modified Rankin score 0-2

ATMOSPHERE Trial design: Patients with symptomatic heart failure were randomized in a 1:1:1 fashion to either aliskiren 300 mg once daily, enalapril 5.

SUSTAIN-6 Trial design: Patients with DM2 at high risk for CV events were randomized in a 1:1:1:1 fashion to either semaglutide 0.5 mg, semaglutide 1 mg,

PROCAMIO Trial design: Patients with hemodynamically stable wide complex monomorphic tachycardia were randomized 1:1 to either intravenous procainamide.

LATITUDE-TIMI 60 Trial design: Patients hospitalized with AMI on guideline-recommended therapy were randomized in a 1:1 fashion to either losmapimod 7.5.

BAT for HFrEF Trial design: Patients with chronic systolic HF were randomized in a 1:1 fashion to either baroreceptor activation therapy (BAT) or control.

ATHENA-HF Trial design: Patients with acute heart failure were randomized to spironolactone 100 mg daily (n = 182) vs. placebo/low-dose spironolactone.

TACTICS-HF Trial design: Patients with acute heart failure (reduced or preserved ejection fraction) were randomized to tolvaptan 30 mg at 0, 24, and 48.

RIDDLE-NSTEMI Trial design: Patients with NSTEMI were randomized to either immediate (within 2 hours) intervention or delayed (within 72 hours) intervention.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Ranolazine in Microvascular Dysfunction

(p = 0.32 for noninferiority)

(p < for noninferiority)

BRAVO-3 Trial design: Patients undergoing transfemoral TAVR were randomized in a 1:1 fashion to bivalirudin or UFH. They were followed for 30 days. Results.

OSLER Trial design: Patients from five phase 2 trials and seven phase 3 trials with evolocumab were invited to participate in the OSLER extension program,

Impedence-guided management

(p for noninferiority < 0.001)

(p = for noninferiority)

ACCELERATE Trial design: Patients at high vascular risk were randomized to either evacetrapib 130 mg daily or placebo. They were followed for 30 months.

POPE-2 Trial design: Patients with moderate to large pericardial effusion after cardiac surgery were randomized to colchicine 2 mg loading dose, then 1.

Enrollment and Outcomes

HOPE-3 Trial design: Patients without known cardiovascular disease, and with an intermediate risk of cardiovascular events, were randomized in a 2 x 2.

TRUE-AHF Trial design: Patients with acute decompensated heart failure were randomized in a 1:1 fashion to either early ularitide infusion (within 12 hours)

STOP-CHAGAS Trial design: Asymptomatic patients with serological evidence of T. cruzi were randomized to posaconazole 400 mg BID, benznidazole 200 mg BID,

Primary safety endpoint

Chest Pain Choice Trial design: Patients presenting to the ED with low risk chest pain were randomized to either use of a tailored decision aid or routine.

MOMENTUM 3 Trial design: Patients with advanced heart failure were randomized to a centrifugal-flow pump (n = 152) vs. an axial-flow pump (n = 142). Results.

IVUS-XPL Trial design: Patients undergoing drug-eluting stent implantation for long coronary lesions were randomized to IVUS-guided PCI (n = 700) vs. angiography-guided.

IMPRESS Trial design: Patients undergoing primary PCI for STEMI and cardiogenic shock were randomized in a 1:1 to either Impella CP or IABP. They were.

NOBLE Trial design: Patients with unprotected left main disease were randomized to either PCI with a drug-eluting stent (DES) (88% biolimus) or CABG. They.

CIRCUS Trial design: Patients with anterior STEMI were randomized to IV cyclosporine 2.5 mg/kg (n = 475) vs. placebo (n = 495) immediately before coronary.

Presentation transcript:

ALPS Trial design: Patients with adult nontraumatic out-of-hospital cardiac arrest (OOHCA) and persistent or recurrent VT/VF after ≥1 shock were randomized in 1:1:1 fashion to either intravenous amiodarone, lidocaine, or placebo. They were followed until hospital discharge. (p = 0.08)* Results Primary outcome, survival to hospital discharge, for amiodarone vs. lidocaine vs. placebo: 24.4% vs. 23.7% vs. 21.0%, p > 0.05 Survival with favorable neurological status: 18.8% vs. 17.5% vs. 16.6%, p = 0.19 and 0.59 vs. placebo Temporary cardiac pacing within 24 hours: 4.9% vs. 3.2% vs. 2.7%, p = 0.02 100 (p = 0.16)** % 50 24.4 23.7 21.0 Conclusions No significant difference in survival to hospital discharge or survival with favorable neurological outcomes among with patients with OOHCA due to VT/VF between amiodarone, lidocaine, or placebo Either drug may be a reasonable choice in these patients given the extremely grim overall prognosis, with a greater numerical benefit with amiodarone Primary endpoint Amiodarone (n = 974) Lidocaine (n = 993) Placebo (n = 1,059) * Amiodarone vs. placebo ** Lidocaine vs. placebo Kudenchuk PJ, et al. N Engl J Med 2016;374:1711-22